[Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)]. 1978

N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D011736 Pyridoxine The 4-methanol form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). Pyridoxin,Pyridoxine Hydrochloride,Pyridoxol,Pyridoxol Hydrochloride,Rodex
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D004296 Dopa Decarboxylase One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease. Decarboxylase, Dopa
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001545 Benserazide An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone. Serazide,Seryltrihydroxybenzylhydrazine,DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide,Ro 4-4602,Seryltrihydroxy Benzylhydrazine,Benzylhydrazine, Seryltrihydroxy,Ro 4 4602,Ro 44602
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D065105 Aromatic Amino Acid Decarboxylase Inhibitors Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. Aromatic-L-Amino-Acid Decarboxylase Inhibitors,DOPA Decarboxylase Inhibitors,Dihydroxyphenylalanine Decarboxylase Inhibitors,Aromatic L Amino Acid Decarboxylase Inhibitors,Decarboxylase Inhibitors, Aromatic-L-Amino-Acid,Decarboxylase Inhibitors, DOPA,Decarboxylase Inhibitors, Dihydroxyphenylalanine,Inhibitors, Aromatic-L-Amino-Acid Decarboxylase,Inhibitors, DOPA Decarboxylase,Inhibitors, Dihydroxyphenylalanine Decarboxylase

Related Publications

N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
October 1975, Lakartidningen,
N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
May 1979, Wiener klinische Wochenschrift,
N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
January 1976, Deutsche medizinische Wochenschrift (1946),
N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
November 1942, The Journal of physiology,
N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
February 1987, Archives internationales de pharmacodynamie et de therapie,
N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
September 1977, Harefuah,
N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
July 1974, MMW, Munchener medizinische Wochenschrift,
N Yoshimine, and F Kuzuya, and K Mori, and N Sakamoto
May 1984, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!